Home » BMS’s Opdivo Flops in Phase 3 Lung-Cancer Study
BMS’s Opdivo Flops in Phase 3 Lung-Cancer Study
Bristol-Myers Squibb revealed that Opdivo failed in a Phase 3 trial testing the drug’s efficacy as a monotherapy.
The trial failed to meet its endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer.
Beyond expressing disappointment in the results, company officials did not specify too what degree the drug failed.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May